FDA Inspection 1166989 — Global Blood Therapeutics, Inc.
The FDA completed an inspection of Global Blood Therapeutics, Inc. on Mar 11, 2022 in South San Francisco, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 11, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- South San Francisco, CA (United States)
Additional details
Postmarket Adverse Drug Experience (PADE)